Completed PHASE2 INTERVENTIONAL 4-arm NCT00515541

Lovaza's Effect on the Activation of Platelets (LEAP)

Effect of the Omega n3 Fatty on Human Platelet Function

Sponsor: Invitrox

Conditions Bleeding Cardiovascular Disease

Interventions Lovaza

Updated 7 times since 2017 Last updated: Jun 27, 2013 Started: Sep 30, 2007 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Bleeding and Cardiovascular Disease and is currently completed. Invitrox leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Invitrox
Reliant Pharmaceuticals

Data source: Invitrox

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.